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1. Introduction  
Desmoplastic melanoma is a rare variant of spindle cell melanoma that was first described 
in 1971 by Conley et al. [1] . Between 1988 and 2006, less than 2,000 patients were diagnosed 
with desmoplastic melanoma in the United States. It accounts for between 1 to 4 percent of 
all cases of cutaneous melanomas. [2] Early diagnosis of desmoplastic melanoma can often 
result in favorable outcomes due to the relatively slow-growing nature of the tumor.  
However, in most patients with desmoplastic melanoma, the diagnosis is usually reached at 
an advanced stage of the disease due to the significant diagnostic challenges associated with 
this tumor. 
2. Epidemiology 
An analysis of the National Cancer Insititute’s Surveillance, Epidemiology and End Results 
(SEER) tumor registry database by Wasif et al in 2010 found that the mean age of onset for 
desmoplastic melanoma to be 66 + 4 and a median age of onset of 69. Compared to other 
cutaneous melanomas, desmoplastic melanoma is more likely to present in an older 
population with a median age of onset about 10 years older. [3]  The study by Wasif et al 
also identified a 65 percent male predominance. [3] A systematic review of literature on 
desmoplastic melanoma by Lens et al in 2005 yielded similar epidemiological data with a 63 
percent male predominance. While desmoplastic melanoma is most likely to occur in older 
men, it can affect men or women of any age. [4] 
Approximately 51 to 53 percent of desmoplastic melanomas are located in the head and 
neck; less common locations included the extremities (26 to 30 percent), and the trunk (18 to 
20 percent). [3, 4]  Although the overall occurrence of desmoplastic melanoma on the 
extremities is uncommon, compared to the lower extremities, the upper extremities appear 
to be a more favored location and represent 70 percent of all desmoplastic melanomas 
occurring on extremities. [4] This distribution for desmoplastic melanoma is similar to the 
pattern of distribution seen in non-melanoma skin cancers, squamous cell carcinoma and 
basal cell carcinoma. Overall, desmoplastic melanoma appears to be more likely to be found 
in chronically sun-exposed areas.  
Desmoplastic melanoma is also frequently associated with other types of skin cancers, 
especially with other cutaneous melanomas that are also associated with sun exposure. [5] 
Desmoplastic melanoma has been reported to occur in conjunction with atypical lentiginous 
hyperplasia, lentigo maligna melanoma, and superficial spreading malignant melanoma. 
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Approximately 30 percent of desmoplastic melanoma occurs in combination with lentigo 
maligna melanoma, also known as a Hutchinson melanotic freckle, which contributes its 
presentation as an atypical pigmented lesion in about half of the cases. [5, 6] 
3. Clinical features 
Desmoplastic melanoma is commonly misdiagnosed due to its subtle presentation. It 
commonly appears as an indurated skin-colored papule, plaque or nodule. These lesions are 
usually painless. [7, 8]  The diagnostic challenge for desmoplastic melanoma is frequently 
attributed to the observation that more than half of all desmoplastic melanomas are 
amelanotic, or not possessing pigmentation. Therefore, they are commonly mistaken for 
benign lesions, such as dermatofibromas or scars. [5] The presence of a new scar without a 
history of trauma may prompt the clinician to consider the possibility of desmoplastic 
melanoma among other differential diagnoses, especially if the scar is located on the head 
and neck region. The differential diagnosis for desmoplastic melanoma also includes basal 
cell carcinomas and dermal nevi, which can also present as pale, skin-colored lesions in the 
head and neck region. As previously stated, desmoplastic melanomas that are associated 
with lentigo melanoma often present with atypical pigmentation patterns that are more 
reminiscent of other subtypes of melanomas and non-melanoma skin cancers. Desmoplastic 
melanomas presenting with atypical pigmentation tend to have better prognosis because 
they are often recognized earlier. Other rare, atypical findings associated with desmoplastic 
melanoma include macular erythema and alopecia. [4] 
4. Histological features 
As with other skin cancers, a biopsy is required to definitively diagnose desmoplastic 
melanoma. The pathological presentation of desmoplastic melanoma is characterized by a 
proliferation of spindle cells, which are non-pigmented spindle-shaped melanocytes. (See 
Figure 1) Cellular atypia can vary widely from near-normal morphology to moderate atypia. 
This can lead to significant diagnostic challenge as the cells may display little atypia in 
many cases. The nuclei of these spindle cells tend to hyperchromatic and may be elongated. 
The cytoplasm is usually scant an increased nucleus to cytoplasm ratio commonly seen in 
malignant cells. [5, 8] 
These spindle cells of desmoplastic melanoma are found in variable distributions among a 
background of reactive fibroblasts and collagen bundles. The appearance of collagen 
bundles is similar to that of a scar; this may account for the scar-like clinical appearance. 
Islands of lymphoid aggregates may also be seen among the collagenous background. Solar 
elastosis is routinely found in the dermis, consistent with the association of desmoplastic 
melanoma with sun exposure.  [5, 8] 
When desmoplastic melanoma invades surrounding nerves, it is desmoplastic neurotropic 
melanoma. In desmoplastic neurotropic melanoma, spindle cells may surround and/or 
invade nerves in the dermis. [9] Spindle cells may also undergo neural transformation to 
form structures resembling nerves. Typically, this occurs only when the tumor exceeds 1.5 
mm in thickness or a Clark stage of greater than IV. [5] Of note, while nerve involvement is 
not uncommon for large tumors, desmoplastic melanomas tend not to invade the vascular 
or lymphatic structures with the same frequency. 
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Fig. 1. Histological features of desmoplastic melanoma  
(photograph courtesy of Dr. Maxwell Fung) 
Immunohistochemistry can a helpful tool to distinguish desmoplastic melanoma from these 
other forms of cutaneous melanoma and from other benign lesions. Desmoplastic 
melanomas are typically positive for S100 protein, P75 growth factor, and negative for 
HMB-45 protein (See Figure 2). [10] Though the S100 marker is currently the most 
commonly used marker to diagnose desmoplastic melanoma in clinical practice, recently, it 
has been suggested that the P75 nerve growth factor may be a more sensitive marker. 
Staining for the P75 nerve growth factor can be used in conjunction with S100 staining for 
increased sensitivity in diagnosing desmoplastic melanoma. [11] 
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Fig. 2. S100 marker staining for desmoplastic melanoma  
(photograph courtesy of Dr. Maxwell Fung) 
5. Treatment 
Desmoplastic melanoma is typically slow-growing but commonly presents in an advanced 
stage due to its insidious nature. The mean Breslow thickness (measured from the granular 
layer of the epidermis to the deepest portion of the tumor) at diagnosis ranges from 2.0 mm 
to 6.5 mm, and most tumors are already Clark stage IV or V at time of diagnosis. 
Neurotropic involvement ranged from 17 to 78 percent. [4]  
As with most skin cancers, surgical excision is the primary treatment modality for 
desmoplastic melanoma. Wide excision with margins of 1-cm to 2-cm is associated with less 
risk of recurrence and better prognostic outcomes. [3] It has even been suggested that 
margins of at least 2-cm are needed for even small lesions. [12]  
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Despite its tendency to recur locally at the primary site, desmoplastic melanoma is less 
likely to have nodal metastases than other forms of cutaneous melanoma. In cases where 
sentinel node biopsies were performed, only 3 percent of these patients were found to have 
involvement of desmoplastic melanoma cells in the sentinel lymph nodes. Therefore, 
controversy exists regarding criteria for selecting appropriate patients with desmoplastic 
melanoma for sentinel lymph node biopsy due to the rare occurrence of nodal invasion. [3, 
12] However, the incidence of lymph node involvement is significantly higher when there is 
nerve involvement, as in DNM. Therefore, sentinel lymph node biopsy is currently 
recommended for DNM. [9]  
The use of post-operative adjuvant radiation for desmoplastic melanoma has been found to 
be effective in decreasing the rate of recurrence. Adjuvant radiation of the local site is 
indicated if margins of the tumor are not clearly defined or intense neurotropic invasion is 
observed. [13] Adjuvant immunotherapy and chemotherapy are not routinely 
recommended for treatment of desmoplastic melanoma, and the use of these modalities has 
not been proven to improve outcomes. [4] 
6. Prognosis 
Comparing tumors of the same stage, prognosis of desmoplastic melanoma is more 
favorable than that of other subtypes of cutaneous melanoma.  However, because 
desmoplastic melanoma is usually diagnosed at a later stage than other cutaneous 
melanoma, is the overall prognosis for desmoplastic melanoma is poorer. For stage I and II 
lesions, the 5-year survival rate is approximately 90 percent; however, only 29 percent of 
cases are diagnosed in stage I. [2] When all stages of the tumor are accounted, the overall 5-
year survival rate from desmoplastic melanoma is 72 percent. [2] Of note, survival in 
desmoplastic melanoma and desmoplastic neurotropic melanoma was found to be 
comparable despite the wider spread of desmoplastic neurotropic melanoma. This may be 
due to the success of adjuvant radiation therapy in treatment of more advanced lesions. [2] 
Desmoplastic melanomas have a high local recurrence rate that ranges from 7 to 56 percent. 
[4] The high local recurrence rate of desmoplastic melanoma may be attributed to difficulties 
in defining surgical margin during resection of the tumor. Local recurrence was more 
common in desmoplastic neurotropic melanoma than in desmoplastic melanomas without 
nerve involvement. [2] For desmoplastic melanomas without neural invasion, rates of 
metastatic disease were generally found to be as low as 7 percent [4] In comparison, 
desmoplastic neurotropic melanoma metastasize at a higher rate of approximately 15 
percent. [9] 
7. Summary 
Desmoplastic melanoma is a rare subtype of cutaneous melanoma that is particular 
challenging to diagnosis due to its atypical amelanotic appearance. Desmoplastic melanoma 
is characterized histologically by the proliferation of atypical spindle-shaped melanocytes, 
and neurotropism is not uncommonly observed with this tumor.  While desmoplastic 
melanoma tends to recur locally at higher frequency compared to other subtypes of 
melanomas, it is less likely to travel to the nodal basin or metastasize. Treatment of 
desmoplastic melanoma relies primarily on surgical excision with wide margins and 
adjuvant radiotherapy for advanced disease. Prognosis tends to be favorable when tumor 
margins are clearly defined and adequate surgical margin is achieved.  
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